Don't Get Burned by the Next Cell Genesys
Senior Columnist Adam Feuerstein re-examines the red flags in the Cell Genesys story so that when the same issues rear their ugly head in another biotech story investors will be better prepared.
10:00AM 10/20/08
Biotech-Stock Mailbag: Genentech
More on the Roche deal for Genentech, the value in Gilead and much more.
12:26PM 07/25/08
Biotech-Stock Mailbag: Genentech, Gilead (RealMoney.com $)
More on the Roche deal for Genentech, the value in Gilead and much more.
06:59AM 07/25/08
Biotech Stocks: Second-Half '08 Preview
Here are the data and regulatory decisions that are likely to be the biggest catalysts from July to December.
10:36AM 07/07/08
Feuerstein's Biotech-Stock Mailbag
Breaking down Introgen's latest data, MiddleBrook's courtship chances, what's right at Gilead, and more.
10:36AM 05/30/08
Feuerstein's Biotech-Stock Mailbag
Cell Genesys' 'news' this week doesn't do much to boost prospects for its prostate cancer vaccine.
10:41AM 02/23/08
Feuerstein's Biotech-Stock Mailbag
Medarex's recent drop in stock price means the FDA isn't likely to approve its melanoma drug soon.
06:38PM 01/06/08
Thursday's Late Winners & Losers
Chordiant inks a big deal with a telecom company.
09:21PM 12/27/07
Top Rocket Stocks for Week of Dec. 24
ValueClick and NetSuite could move higher.
10:27AM 12/26/07
Biotech Notebook: Genitope, Amicus
Failing a phase III trial is never a good thing. Don't believe a CEO's attempt to spin it otherwise.
01:44PM 12/21/07
Thursday's Late Winners & Losers
RIMM benefited from the explosive demand for Blackberry's.
08:44PM 12/20/07
Genitope's MyVax Vaccine Falls Short
The stock gets crushed after the drug can't meet its endpoint.
04:12PM 12/20/07



Connect with TheStreet